After years of decline,
drugmakers' price hikes may have bottomed out
|
|
Inflation in 2021 may have offered drugmakers a catalyst for taking slightly bigger increases on a list price basis. But rebates to insurers are still keeping net price rises lower.
No comments:
Post a Comment